checkAd

     430  0 Kommentare SuperSonic Imagine Announces Clinical Data From Its Retrospective Multicenter Trial Evaluating ShearWave(TM) Elastography for the Non-Invasive Staging of Patients With Chronic Liver Disease - Seite 2

                     
                     
    Fibrosis Stage   All patients   HCV   HBV   NAFLD
    ≤1 vs. ≥2   86%   86%   92%   86%
    ≤2 vs. ≥3   91%   93%   94%   92%
    ≤3 vs. 4   95%   96%   97%   96%
                     
                     

    This analysis demonstrated the remarkable ability of SWE™ to determine liver disease severity in a broad range of patients. Specifically, the results revealed the ability to accurately evaluate liver disease caused by hepatitis C, hepatitis B and non-alcoholic fatty liver disease including NASH (non-alcoholic steatohepatitis).

    Seite 2 von 4





    Verfasst von Marketwired
    SuperSonic Imagine Announces Clinical Data From Its Retrospective Multicenter Trial Evaluating ShearWave(TM) Elastography for the Non-Invasive Staging of Patients With Chronic Liver Disease - Seite 2 AIX-EN-PROVENCE, FRANCE--(Marketwired - Apr 28, 2015) - SuperSonic Imagine (EURONEXT PARIS: SSI) (Euronext: SSI, FR0010526814) whose ShearWave Elastography™ (SWE™) and Ultrafast™ Doppler technologies have revolutionized the ultrasound imaging …

    Schreibe Deinen Kommentar

    Disclaimer